News

Luminoah closes $6M Series A round

Charlottesville medical device company Luminoah Inc. has closed a $6 million Series A round it says it will use to complete the development of its mobile feeding tube device that collects data.

The round was led by Charlottesville’s Fry’s Path Capital and included participation from Arlington’s Sands Capital, Charlottesville’s CAV Angels, Virginia Beach’s 757 Angels and Richmond’s Virginia Venture Partners — the equity investment arm of the Virginia Innovation Partnership Corp.

Luminoah, which took top honors at the Light House Labs’ Demo Day competition last month, says its device lets patients to keep a more mobile lifestyle while on a feeding tube. Its data-tracking features also allow remote patient monitoring.

CEO Neal Piper started the company after his young son was diagnosed with cancer and required a constraining feeding tube.

“It’s just a no-brainer to let a kid be active while you pump nutrition into their stomach,” Piper told Richmond Inno last month.

Piper said the goal is to apply for Food and Drug Administration approval in 2024. Luminoah wants to go after the pediatric home health care market initially, but also seeks to move into senior and rehabilitation markets. The company says the enteral feeding technology market is worth about $12 billion and that half-a-million children could benefit from its product.

Learn more here.

Recent News

10/28/2026

U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …

10/26/2026

ATCC Selected by ARPA-H to Support Next-Generation BioStabilization Technologies

ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program. Through this program, BoSS is taking the “200-degree leap,” from -196°C toward room temperature, to make life-saving cell therapies as easy to store and ship as …

10/26/2026

Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases, today announced that Celia Economides, the Company’s current Executive Vice President of Finance, is expected to be appointed Chief Financial Officer effective promptly after the Company’s reconvened 2026 Annual Meeting of Stockholders, if certain …